This implies that the inactivation mutations of JAK1 and JAK2 block the IFN-γ signaling pathway, leading to downregulation of tumor PD-L1 expression, so it would be unnecessary to attempt anti-PD-L1 therapy in this case. The gene discussed is CD274; the disease is neoplasm.